{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:10:28Z","timestamp":1761333028425,"version":"build-2065373602"},"reference-count":29,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Psoriasis (Pso) is a common chronic inflammatory disease affecting the\nskin, both sexes, and all ages. It can be associated with other chronic inflammatory musculoskeletal\ndisorders and certain drugs, including tumor necrosis factor \u03b1 (TNF\u03b1) antagonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation:<\/jats:title>\n                    <jats:p>A 64-year-old man with seronegative rheumatoid arthritis (RA) refractory to leflunomide\nand prednisone was treated with SB-4 (Benepali), an etanercept biosimilar 50mg\/week\nsubcutaneously. He responded well to the treatment, but a year later, he developed erythematous\nskin eruptions affecting mainly in the palms of both hands. Skin biopsy showed a picture compatible\nwith Pso. SB-4 was discontinued, and the skin lesions disappeared with the addition of topical\nsteroid therapy. This is the only case of psoriatic skin lesions associated with SB-4 treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Thus, we review and discuss the relevant literature of Pso cases related to SB-4 and\nother anti-TNF\u03b1 biosimilars. Rheumatologists dealing with patients on anti-TNF\u03b1 biosimilars\nshould be aware of and recognize these complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1573397116666201119151349","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T23:19:17Z","timestamp":1605827957000},"page":"267-270","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review"],"prefix":"10.2174","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-5722","authenticated-orcid":true,"given":"Eleftherios","family":"Pelechas","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Rheumatology Clinic, Medical School, University of Ioannina, Ioannina,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3932-6652","authenticated-orcid":true,"given":"Alexandra","family":"Papoudou-Bai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Medical School, University of Ioannina, Ioannina,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-2284","authenticated-orcid":true,"given":"Paraskevi V.","family":"Voulgari","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rheumatology Clinic, Medical School, University of Ioannina, Ioannina,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-0326","authenticated-orcid":true,"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rheumatology Clinic, Medical School, University of Ioannina, Ioannina,Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1741-7015-11-88","volume":"11","author":"Rosman Z.","year":"2013","unstructured":"Rosman Z.; Shoenfeld Y.; Zandman-Goddard G.; Biologic therapy for autoimmune diseases: an update. BMC Med 2013,11,88","journal-title":"BMC Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","volume":"61","author":"Pichler W.J.","year":"2006","unstructured":"Pichler W.J.; Adverse side-effects to biological agents. Allergy 2006,61(8),912-920","journal-title":"Allergy"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00002281-200307000-00003","volume":"15","author":"Sfikakis P.P.","year":"2003","unstructured":"Sfikakis P.P.; Kollias G.; Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 2003,15(4),380-386","journal-title":"Curr Opin Rheumatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","volume":"126","author":"Lin J.","year":"2008","unstructured":"Lin J.; Ziring D.; Desai S.; Kim S.; Wong M.; Korin Y.; Braun J.; Reed E.; Gjertson D.; Singh R.R.; TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008,126(1),13-30","journal-title":"Clin Immunol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.amjmed.2005.01.029","volume":"118","author":"Voulgari P.V.","year":"2005","unstructured":"Voulgari P.V.; Alamanos Y.; Nikas S.N.; Bougias D.V.; Temekonidis T.I.; Drosos A.A.; Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 2005,118(5),515-520","journal-title":"Am J Med"},{"key":"ref=6","first-page":"31","volume":"30","author":"Markatseli T.E.","year":"2012","unstructured":"Markatseli T.E.; Alamanos Y.; Saougou I.; Voulgari P.V.; Drosos A.A.; Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Clin Exp Rheumatol 2012,30(1),31-38","journal-title":"Clin Exp Rheumatol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"rkz007","DOI":"10.1093\/rap\/rkz007","volume":"3","author":"Papadopoulos C.G.","year":"2019","unstructured":"Papadopoulos C.G.; Gartzonikas I.K.; Pappa T.K.; Markatseli T.E.; Migkos M.P.; Voulgari P.V.; Drosos A.A.; Eight-year survival study of first-line tumour necrosis factor &#x3B1; inhibitors in rheumatoid arthritis: real-world data from a university centre registry. Rheumatol Adv Pract 2019,3(1),rkz007","journal-title":"Rheumatol Adv Pract"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.semarthrit.2010.07.004","volume":"40","author":"Saougou I.","year":"2011","unstructured":"Saougou I.; Markatseli T.E.; Papagoras C.; Voulgari P.V.; Alamanos Y.; Drosos A.A.; Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 2011,40(5),398-406","journal-title":"Semin Arthritis Rheum"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00296-007-0330-9","volume":"27","author":"Venetsanopoulou A.I.","year":"2007","unstructured":"Venetsanopoulou A.I.; Voulgari P.V.; Alamanos Y.; Papadopoulos C.G.; Markatseli T.E.; Drosos A.A.; Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. Rheumatol Int 2007,27(10),935-939","journal-title":"Rheumatol Int"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jbspin.2010.02.014","volume":"77","author":"Saougou I.","year":"2010","unstructured":"Saougou I.; Markatseli T.E.; Voulgari P.V.; Drosos A.A.; Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. Joint Bone Spine 2010,77(4),325-329","journal-title":"Joint Bone Spine"},{"key":"ref=11","first-page":"415","volume":"32","author":"Markatseli T.E.","year":"2014","unstructured":"Markatseli T.E.; Papagoras C.; Nikoli A.; Voulgari P.V.; Drosos A.A.; Certolizumab for rheumatoid arthritis. Clin Exp Rheumatol 2014,32(3),415-423","journal-title":"Clin Exp Rheumatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"E387","DOI":"10.3390\/jcm8030387","volume":"8","author":"Pelechas E.","year":"2019","unstructured":"Pelechas E.; Voulgari P.V.; Drosos A.A.; Golimumab for Rheumatoid Arthritis. J Clin Med 2019,8(3),E387","journal-title":"J Clin Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/art.21233","volume":"52","author":"Sfikakis P.P.","year":"2005","unstructured":"Sfikakis P.P.; Iliopoulos A.; Elezoglou A.; Kittas C.; Stratigos A.; Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005,52(8),2513-2518","journal-title":"Arthritis Rheum"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/ard.2007.075663","volume":"67","author":"Voulgari P.V.","year":"2008","unstructured":"Voulgari P.V.; Markatseli T.E.; Exarchou S.A.; Zioga A.; Drosos A.A.; Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008,67(4),567-570","journal-title":"Ann Rheum Dis"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/03009740902922612","volume":"38","author":"Exarchou S.A.","year":"2009","unstructured":"Exarchou S.A.; Voulgari P.V.; Markatseli T.E.; Zioga A.; Drosos A.A.; Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand J Rheumatol 2009,38(5),328-331","journal-title":"Scand J Rheumatol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14712598.2019.1566456","volume":"19","author":"Pelechas E.","year":"2019","unstructured":"Pelechas E.; Drosos A.A.; Etanercept biosimilar SB-4. Expert Opin Biol Ther 2019,19(3),173-179","journal-title":"Expert Opin Biol Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/archderm.143.2.223","volume":"143","author":"de Gannes G.C.","year":"2007","unstructured":"de Gannes G.C.; Ghoreishi M.; Pope J.; Russell A.; Bell D.; Adams S.; Shojania K.; Martinka M.; Dutz J.P.; Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007,143(2),223-231","journal-title":"Arch Dermatol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"Gasparyan A.Y.","year":"2011","unstructured":"Gasparyan A.Y.; Ayvazyan L.; Blackmore H.; Kitas G.D.; Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 2011,31(11),1409-1417","journal-title":"Rheumatol Int"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"Aletaha D.","year":"2010","unstructured":"Aletaha D.; Neogi T.; Silman A.J.; Funovits J.; Felson D.T.; Bingham C.O.; Birnbaum N.S.; Burmester G.R.; Bykerk V.P.; Cohen M.D.; Combe B.; Costenbader K.H.; Dougados M.; Emery P.; Ferraccioli G.; Hazes J.M.; Hobbs K.; Huizinga T.W.; Kavanaugh A.; Kay J.; Kvien T.K.; Laing T.; Mease P.; M&#xE9;nard H.A.; Moreland L.W.; Naden R.L.; Pincus T.; Smolen J.S.; Stanislawska-Biernat E.; Symmons D.; Tak P.P.; Upchurch K.S.; Vencovsk&#xFD; J.; Wolfe F.; Hawker G.; 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010,62(9),2569-2581","journal-title":"Arthritis Rheum"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"Naranjo C.A.","year":"1981","unstructured":"Naranjo C.A.; Busto U.; Sellers E.M.; Sandor P.; Ruiz I.; Roberts E.A.; Janecek E.; Domecq C.; Greenblatt D.J.; A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981,30(2),239-245","journal-title":"Clin Pharmacol Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","volume":"137","author":"Her M.","year":"2016","unstructured":"Her M.; Kavanaugh A.; Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 2016,137(1),19-27","journal-title":"J Allergy Clin Immunol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"i94","DOI":"10.1093\/rheumatology\/kev088.111","volume":"54","author":"Reilly E.","year":"2015","unstructured":"Reilly E.; Edwards C.; Mackay K.; Anti-TNF therapy induced arthritis in patients with inflammatory bowel disease. Oxford (Rheumatology) 2015,54,i94","journal-title":"Oxford (Rheumatology)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/rheumatology\/ken091","volume":"47","author":"Cobo-Ib&#xE1;&#xF1;ez T.","year":"2008","unstructured":"Cobo-Ib&#xE1;&#xF1;ez T.; del Carmen Ord&#xF3;&#xF1;ez M.; Mu&#xF1;oz-Fern&#xE1;ndez S.; Madero-Prado R.; Mart&#xED;n-Mola E.; Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 2008,47(5),731-732","journal-title":"Rheumatology (Oxford)"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/apt.15370","volume":"50","author":"Korzenik J.","year":"2019","unstructured":"Korzenik J.; Larsen M.D.; Nielsen J.; Kjeldsen J.; N&#xF8;rg&#xE5;rd B.M.; Increased risk of developing Crohn\u2019s disease or ulcerative colitis in 17&#xA0;018 patients while under treatment with anti-TNF&#x3B1; agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther 2019,50(3),289-294","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.autrev.2013.06.005","volume":"13","author":"Fiorino G.","year":"2014","unstructured":"Fiorino G.; Danese S.; Pariente B.; Allez M.; Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-&#x3B1; agents. Autoimmun Rev 2014,13(1),15-19","journal-title":"Autoimmun Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/ajg.2015.205","volume":"110","author":"Fr&#xE9;ling E.","year":"2015","unstructured":"Fr&#xE9;ling E.; Baumann C.; Cuny J.F.; Bigard M.A.; Schmutz J.L.; Barbaud A.; Peyrin-Biroulet L.; Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol 2015,110(8),1186-1196","journal-title":"Am J Gastroenterol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1084\/jem.20050500","volume":"202","author":"Nestle F.O.","year":"2005","unstructured":"Nestle F.O.; Conrad C.; Tun-Kyi A.; Homey B.; Gombert M.; Boyman O.; Burg G.; Liu Y.J.; Gilliet M.; Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005,202(1),135-143","journal-title":"J Exp Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1073\/pnas.0408506102","volume":"102","author":"Palucka A.K.","year":"2005","unstructured":"Palucka A.K.; Blanck J.P.; Bennett L.; Pascual V.; Banchereau J.; Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005,102(9),3372-3377","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","volume":"161","author":"Seneschal J.","year":"2009","unstructured":"Seneschal J.; Milpied B.; Vergier B.; Lepreux S.; Schaeverbeke T.; Ta&#xEF;eb A.; Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009,161(5),1081-1088","journal-title":"Br J Dermatol"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397116666201119151349","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/188200\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397116666201119151349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:04:58Z","timestamp":1761332698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/188200\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397116666201119151349","relation":{},"ISSN":["1573-3971"],"issn-type":[{"type":"print","value":"1573-3971"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}